PSMA-targeted radiopharmaceuticals have brought theranostics into the clinical spotlight—but what comes next? In this episode, host Dr. Mike Nickels is joined by Dr. Anna Wu (City of Hope) for a wide-ranging discussion on the future of theranostics beyond PSMA. Together, they explore what makes a strong theranostic target, how evolving tumor biology and heterogeneity are shaping next-generation agents, and why pan-cancer and tumor-microenvironment targets are gaining momentum. The conversation also dives into combination strategies, alpha-emitters, clinical translation challenges, and what the next decade may hold for the field. A must-listen for scientists, clinicians, and anyone interested in where theranostics is headed next.

This special episode, produced in collaboration with the Canadian Nuclear Isotope Council (CNIC), features James Scongack - the CNIC’s Chair and COO of Bruce Power - discussing Canada’s global leadership in medical isotope production. From cobalt-60 to lutetium-177, learn how Canada is investing in infrastructure, building cross-border partnerships, and scaling up to meet the growing demand for radiotheranostics.

In this episode, host Dr. Mike Nickels welcomes nuclear medicine pioneer Dr. Richard Wahl for an in-depth exploration of alpha-emitting radiopharmaceuticals. Learn where alpha therapy holds the most clinical promise, and what’s needed to bring these powerful agents into routine care. From supply chain hurdles to toxicity management and future clinical applications, this conversation offers expert insight into one of the most exciting—and complex—frontiers in nuclear medicine.